Invenux, LLC, a privately held clinical stage biopharmaceutical company, is propelling its research and clinical trials forward to treat sickle cell disease in the U.S. and worldwide. By developing a botanical medicine approach, Invenux aims to break down barriers to save and change the lives of sickle cell disease patients.
Colorado BioScience Association President and CEO, Elyse Blazevich, asked Robert Swift, Managing Member of Invenux, CBSA’s Key Questions for Life Sciences Innovators.
Q: Tell us about your company or organization.
A: We are focused on R&D of drugs for rare diseases. Our first drug candidate is SCD-101 for the treatment of sickle cell disease (SCD). We are also developing drugs to treat Mucopolysaccharidosis I and III. SCD, the first genetic disease identified over 60…
Click here to view original post
